FW: NATAP: Cancer Drug Tested as HCV Therapy
- New HCV drug study: cancer drug Tarvacin
Peregrine Pharmaceuticals this week announced it is ramping up testing of
its cancer drug Tarvacin as a hepatitis C treatment. The Phase I study is
enrolling patients with hepatitis C rather than healthy subjects. Enrollment
is several months ahead of schedule and should be completed by February; the
release of preliminary data should begin by February 27. Tarvacin is
Peregrine's first drug using its antiphospholipid technology. Certain viral
diseases cause aminophospholipids, which are parts of the cell membrane, to
become exposed. Phospholipids envelop the viruses, making them a target for
the therapy. (AP)
NATAP nataphcv mailing list -- nataphcv@...
This is an annoucement-only mailing list. Do not reply.
To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.
For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv
[Non-text portions of this message have been removed]